Novo-Nordisk stock heads into the open after a 1.6% slide
Published on 09/16/2026 at 07:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 15, 2026, Novo-Nordisk stock finished at DKK 275.90 on Nasdaq Copenhagen, down 1.6% from the prior session. Compared with the OMX Copenhagen 20 index, which slipped about 0.84% that day, the shares showed a steeper decline, signaling relative weakness in the Danish blue-chip benchmark.
September 15, 2026 in numbers
Novo-Nordisk A/S (ISIN DK0062498333) saw its Class B shares end the September 15, 2026 session at DKK 275.90 on Nasdaq Copenhagen after a 1.6% loss, according to Investing.com data for the Danish market close. The same market wrap noted that the OMX Copenhagen 20 index fell 0.84% on September 15, 2026, placing Novo-Nordisk among the weaker constituents as it declined 4.50 points to its closing level. Trading volume and the precise intraday high and low for Novo-Nordisk on Nasdaq Copenhagen were not highlighted in the wrap, but the closing print at DKK 275.90 fits within the broader price range implied by recent buyback transactions at an average of DKK 281.89 per B share as disclosed on September 11, 2026 in a company share repurchase update reported by StockTitan. Relative to that buyback average, the September 15, 2026 close was DKK 5.99 lower, underscoring that the stock is trading below the levels at which the company has been repurchasing shares.
Sentiment toward Novo-Nordisk on September 15, 2026 was constrained by a cautious analyst stance. As Börsen-Zeitung reported on September 15, 2026, Deutsche Bank Research reiterated a Sell rating on Novo-Nordisk with a price target of DKK 265, below the DKK 275.90 close and implying further downside from current levels. The combination of a weaker index backdrop and a reaffirmed Sell recommendation helped to frame the stock’s underperformance versus the OMX Copenhagen 20 on September 15, 2026.
Outlook today, September 16, 2026
Looking at the immediate calendar, Novo-Nordisk’s latest update on its 2026 share buyback program was published for the period up to September 11, 2026, with no specific company event dated for September 16, 2026 in that communication, as highlighted by TipRanks. Broader market factors remain relevant: Denmark’s equity market tone, captured by moves in the OMX Copenhagen 20, can continue to influence Novo-Nordisk today, especially if risk appetite for healthcare and obesity-drug names shifts in response to sector news summarized by outlets such as 24/7 Wall St. In addition, investor attention today is likely to remain on how Novo-Nordisk balances ongoing share repurchases with investment needs in its obesity and diabetes franchises, given the scale of the DKK 9.3 billion buyback program detailed in recent filings and announcements.
